clinical trial · NCT04800822
PF-07284892 in Participants With Advanced Solid Tumors
Solid TumorPF-07284892lorlatinibbinimetinibcetuximabencorafenib
brief summary
The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.
started
Mar 17, 2021
primary completion
Jun 19, 2024
completion
Jun 19, 2024
last updated
Jun 4, 2026
official title
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol